Hematologic Oncology | Specialty

Lisaftoclax With or Without Rituximab or Acalabrutinib Elicits Favorable Responses and Safety in CLL/SLL

December 23rd 2022

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

December 23rd 2022

The FDA has approved mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Evolution of Targeted Therapy Improves Clinical Benefit in Blood and Bone Marrow Cancers

December 22nd 2022

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

Role of Symptom Burden in Thrombocythemia and Polycythemia Vera

December 22nd 2022

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Overview on Essential Thrombocythemia and Polycythemia Vera Management

December 22nd 2022

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents Within the IMerge Phase 2 Study

December 22nd 2022

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

December 21st 2022

Brian A Jonas, MD, reviews the results of the phase 1 study evaluating the use of uproleselan in combination with azacitidine and venetoclax in patients that are older or unfit for treatment naïve acute myeloid leukemia (AML).

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

December 21st 2022

Harry Erba, MD, PhD shares an update from the recent ASH 2022 Annual Meeting on a phase 1/2 trial of the menin-KMT2A (MLL) Inhibitor ziftomenib in patients with relapsed or refractory acute myeloid leukemia.

Obecabtagene Autoleucel Meets Primary End Point of ORR in R/R B-cell Acute Lymphoblastic Leukemia

December 20th 2022

Obecabtagene autoleucel elicited an overall remission rate of 70% in 50 efficacy-evaluable adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, meeting the primary end point of the phase 2 FELIX trial.

Glofitamab Induces 39% CR Rate in Relapsed/Refractory DLBCL

December 20th 2022

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, demonstrated promising results in patients with relapsed/refractory diffuse large B-cell lymphoma who received at least 2 prior lines of therapy.

Uproleselan Added to Cladribine Plus Low-Dose Cytarabine (LDAC) In Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

December 19th 2022

Tapan M. Kadia, MD evaluates the use of uproleselan, an E-selectin antagonist, in combination with LDAC and Cladribine in patients with treated secondary acute myeloid leukemia.

Biomarker Testing Informs Individualized Diagnosis and Treatment of Low- to Intermediate-Risk AML

December 16th 2022

Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.

Novel Targeted Immunotherapies Strengthen Frontline Treatment Strategies in Hodgkin Lymphoma

December 15th 2022

Joshua Brody, MD, discusses unmet needs in patient subgroups within Hodgkin lymphoma, recent advancements in the use of antibody-drug conjugates such as brentuximab vedotin and anti–PD-1 therapies in earlier lines of therapy, and future avenues for expanding the use of immunotherapy in this tumor type.

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

December 14th 2022

Dr Leif Stenke reviews data on XS004 in patients with chronic myeloid leukemia (CML) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic Regimens

December 13th 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

December 13th 2022

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

GVHD Prophylactic Regimen Improves 1-Year GRFS Vs Standard in Patients With Hematologic Malignancies Post-HCT

December 13th 2022

Administration of cyclophosphamide, tacrolimus, and mycophenolate mofetil improved 1-year GVHD relapse-free survival compared with tacrolimus plus methotrexate in patients with hematologic malignancies undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation.

Olverembatinib Elicits Efficacy in US Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALL

December 13th 2022

Olverembatinib elicited encouraging responses and tolerability in US patients with ponatinib-resistant chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and in patients with CML whose tumors have a T315I mutation.

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

December 13th 2022